Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging

NCT04078178 is registered in ClinicalTrials.gov with Steven E Arnold, MD as lead sponsor.

NCT NCT04078178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04078178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging
Lead sponsor
Steven E Arnold, MD
Phase
Not applicable
Overall status
Completed
Start date
October 30, 2020
Completion date
September 30, 2022
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognition disorders in old age, cognitive decline, mild cognitive impairment